Analysis of domestic prices and reference costs of Lurbinectedin in 2025

Lurbinectedin (Lurbinectedin), as a new anti-cancer drug, has received widespread attention for its launch in the domestic market. In 2025, the original drug Rubicatin has been officially approved for marketing in China, but the specific sales price has not yet been announced. Patients still need to obtain the latest price information through regular hospitals and pharmacies before purchasing. Since this drug is an innovative targeted anti-tumor drug, its research and development costs are high, so the price is expected to be high, and patients need to budget well.

In the Hong Kong market, the reference price of Rubicatin’s original drug is about RMB 20,000 per box of 4 mg. The actual purchase price may fluctuate due to exchange rates and supply conditions. This price level reflects the cost positioning of the drug in the Asian market, and also provides domestic patients with a reference for cross-border purchases. Considering that this drug requires professional hospital use guidance and monitoring, patients also need to consider related medical expenses when using it.

In overseas markets, the prices of Rubicatin’s original drugs vary significantly. The price of each box of the American version is about 90,000 yuan, while the price of the Singapore version is about 30,000 yuan. These price differences are mainly affected by origin, logistics costs and market pricing strategies. Currently, there are no generic rubicatin drugs on the market for sale in overseas markets. Therefore, if patients need to purchase drugs, they can only choose the original drug, which further increases the overall treatment cost.
Taken together, as a new anti-cancer drug, the price of rubicatin is at a relatively high level both domestically and overseas. Before using it, patients should fully understand the source, purchase channels and price information of the drug, and make reasonable plans based on their own economic conditions and medical insurance reimbursement policies. In the future, with the development and launch of generic drugs, prices are expected to drop, providing more patients with more accessible treatment options.
Reference: https://www.drugs.com/